The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc's drug remdesivir.
PFIZER RECALLS SOME BATCHES OF BLOOD PRESSURE DRUG OVER CARCINOGEN PRESENCE
The move comes months after the agency expanded the drug's emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok